Search

Your search keyword '"Zaja F"' showing total 166 results
Start Over Author "Zaja F" Database OpenAIRE
166 results on '"Zaja F"'

1. Immune thrombocytopenia

Author

Bussel J., Cooper N., Boccia R., Zaja F., Newland A., Bussel, J., Cooper, N., Boccia, R., Zaja, F., and Newland, A.

Subjects
Adult, corticosteroid, Purpura, Thrombocytopenic, Idiopathic, fostamatinib, Hematology, Thrombocytopenia, splenectomy, corticosteroids, Immune thrombocytopenia, guidelines, rituximab, thrombopoietin receptor agonists, Quality of Life, Splenectomy, Humans, Rituximab, guideline
Abstract

Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count (

Published
2021

2. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study

Author

Rule, S, Barreto, WG, Briones, J, Carella, AM, Casasnovas, O, Pocock, C, Wendtner, CM, Zaja, F, Robson, S, MacGregor, L, Tschopp, RR, Nick, S, and Dreyling, M

Abstract

Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged maintenance with rituximab provides additional benefit. The phase III MabCute study enrolled 692 patients with relapsed or refractory indolent non-Hodgkin lymphoma. Patients who responded to induction with rituximab plus chemotherapy and were still responding after up to 2 years' initial maintenance with subcutaneous rituximab were randomized to extended maintenance with subcutaneous rituximab (n=138) or observation only (n=138). The primary endpoint of investigator-assessed progression-free survival in the randomized population was un-addressed by the end of study because of an insufficient number of events (129 events were needed for 80% power at 5% significance if approximately 330 patients were randomized). In total, there were 46 progression-free survival events, 19 and 27 in the rituximab and observation arms, respectively (P=0.410 by stratified log-rank test; hazard ratio 0.76 [95% confidence interval: 0.37-1.53]). The median progression-free survival was not reached in either randomized arm. There were no new safety signals; however, adverse events were seen slightly more frequently with rituximab than with observation during extended maintenance. Maintenance for up to 2 years with rituximab after response to initial induction therefore remains the standard of care in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Published
2022

3. Corrigendum: 'Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience' (Leukemia Research (2022) 114, (106803), (S0145212622000297), (10.1016/j.leukres.2022.106803))

Author

De Bellis, E., Imbergamo, S., Candoni, A., Lico, A., Tanasi, I., Mauro, E., Mosna, F., Leoncin, M., Stulle, M., Griguolo, D., Pravato, S., Trentin, L., Lazzarotto, D., Di Bona, E., Sancetta, R., Lucchini, E., Poiani, M., Palmieri, C., and Zaja, F.

Published
2022

4. Corrigendum to 'Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience' [Leukemia Res. 114 (March 2022) 106803](S0145212622000297)(10.1016/j.leukres.2022.106803)

Author

De Bellis, E., Imbergamo, S., Candoni, A., Lico, A., Tanasi, I., Mauro, E., Mosna, F., Leoncin, M., Stulle, M., Griguolo, D., Pravato, S., Trentin, L., Lazzarotto, D., Di Bona, E., Sancetta, R., Lucchini, E., Poiani, M., Palmieri, C., and Zaja, F.

Published
2022

5. SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

Author

Pozzo, F, Bittolo, T, Tissino, E, Vit, F, Vendramini, E, Laurenti, L, D'Arena, G, Olivieri, J, Pozzato, G, Zaja, F, Chiarenza, A, Di Raimondo, F, Zucchetto, A, Bomben, R, Rossi, Fm, Del Poeta, G, Dal Bo, M, Gattei, V., Pozzo, F, Bittolo, T, Tissino, E, Vit, F, Vendramini, E, Laurenti, L, D'Arena, G, Olivieri, J, Pozzato, G, Zaja, F, Chiarenza, A, Di Raimondo, F, Zucchetto, A, Bomben, R, Rossi, Fm, Del Poeta, G, Dal Bo, M, and Gattei, V.

Subjects
Down-Regulation, Article, NOTCH1, immune system diseases, hemic and lymphatic diseases, Humans, CD20, Receptor, Notch1, Antigens, Chronic, neoplasms, CLL, SF3B1, Notch1, Leukemia, B-Cell, Antigens, CD20, Phosphoproteins, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic, Settore MED/15 - MALATTIE DEL SANGUE, embryonic structures, Mutation, cardiovascular system, RNA Splicing Factors, Receptor
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a low CD20 expression, in part explained by an epigenetic-driven downregulation triggered by mutations of the NOTCH1 gene. In the present study, by taking advantage of a wide and well-characterized CLL cohort (n=537), we demonstrate that CD20 expression is downregulated in SF3B1-mutated CLL in an extent similar to NOTCH1-mutated CLL. In fact, SF3B1-mutated CLL cells show common features with NOTCH1-mutated CLL cells, including a gene expression profile enriched of NOTCH1-related gene sets and elevated expression of the active intracytoplasmic NOTCH1. Activation of the NOTCH1 signaling and down-regulation of surface CD20 in SF3B1-mutated CLL cells correlate with over-expression of an alternatively spliced form of DVL2, a component of the Wnt pathway and negative regulator of the NOTCH1 pathway. These findings are confirmed by separately analyzing the CD20-dim and CD20-bright cell fractions from SF3B1-mutated cases as well as by DVL2 knock-out experiments in CLL-like cell models. Altogether, the clinical and biological features that characterize NOTCH1-mutated CLL may also be recapitulated in SF3B1-mutated CLL, contributing to explain the poor prognosis of this CLL subset and providing the rationale for expanding novel agents-based therapies to SF3B1-mutated CLL.

Published
2020

6. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Author

Bastidas, A, de la Serna, J, El Idrissi, M, Oostvogels, L, Quittet, P, Lopez-Jimenez, J, Vural, F, Pohlreich, D, Zuckerman, T, Issa, NC, Gaidano, G, Lee, JJ, Abhyankar, S, Solano, C, de Oteyza, JP, Satlin, MJ, Schwartz, S, Campins, M, Rocci, A, Llamas, CV, Lee, DG, Tan, SM, Johnston, AM, Grigg, A, Boeckh, MJ, Campora, L, Lopez-Fauqued, M, Heineman, TC, Stadtmauer, EA, Sullivan, KM, Alonso, AA, Anagnostopoulos, A, Andreadis, C, Angelopoulou, M, Anttila, VJ, Aoun, M, Barista, I, Berkahn, L, Bloor, AJC, Broady, R, Brossart, P, Buadi, FK, Bulabois, CE, Cantin, G, Cellini, C, Chandrasekar, PH, Chauncey, T, Cuneo, A, Dadwal, SS, Dickinson, M, Eom, H, Sanfeliu, AE, Coll, CF, Flomenberg, PR, Gonzalez-Rodriguez, AP, Gottlieb, DJ, Grisariu, S, Guenther, A, Gutman, J, Hahn, U, Heinz, WJ, Heras, I, Ikeda, T, Jarque, I, Karthaus, M, Kerre, T, Kiani, A, Klein, AK, Kofla, G, Kryuchkova, IV, Kuo, CY, Kuruvilla, J, Kuvshinov, A, Kwak, JY, Lee, JH, Lepretre, S, Lie, AKW, Lucchesi, A, Maertens, J, Marijt, EWA, Munoz, CM, Michieli, M, Milliken, ST, Milpied, N, Coll, JM, Mossad, SB, Murphy, J, Matilla, MBN, Novak, J, Olney, HJ, Navarrete, RO, Cascon, MJP, Peniket, A, Penka, G, Piatkowska-Jakubas, B, Zarzuela, MP, Quiel, D, Rowley, SD, Sabry, W, Salmi, TM, Selleslag, DLD, Shea, TC, Silling, G, Sinisalo, UM, Sohn, SK, Staib, P, Szer, J, Theunissen, K, Topcuoglu, P, Tyurina, NG, Uvarov, M, Wahid, FSA, San Segundo, LY, Yegin, ZA, Yeh, SP, Yip, SF, Yoon, SS, Young, JAH, Zachee, P, Zaja, F, and ZOE-HSCT Study Grp Collaborators

Abstract

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P

Published
2019

7. SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS

Author

Carpenedo, M, Cantoni, S, Mazzucconi, MG, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Zaja, F, Artoni, A, Trentin, L, Ferrara, F, Barcellini, W, Caramazza, D, Rossi, E, Baldacci, E, Ciminello, A, Carbone, C, Cairoli, R, Carpenedo, M, Cantoni, S, Mazzucconi, M, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Zaja, F, Artoni, A, Trentin, L, Ferrara, F, Barcellini, W, Caramazza, D, Rossi, E, Baldacci, E, Ciminello, A, Carbone, C, and Cairoli, R

Subjects
Hematology
Published
2017

8. FRONT-LINE THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE, OFATUMUMAB (FC-O2) IN YOUNG (<= 65 YRS) AND FIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. RESULTS OF THE PROSPECTIVE PHASE 2 GIMEMA STUDY LLC0911

Author

Mauro, Fr, Molica, S, Zaja, F, Piciocchi, A, Ilariucci, F, Coscia, M, Carella, Am, Re, F, Liberati, Am, Tedeschi, A, Gozzetti, A, Cuneo, A, Cortelezzi, A, Baraldi, A, Del Poeta, G, Musolino, C, Battistini, R, De Propris, Ms, Della Starza, I, Raponi, S, Ilari, C, Cafforio, L, Nanni, M, Fazi, P, Vignetti, M, Russo, F, Porrazzo, M, Riemma, C, Specchia, G, Neri, A, Guarini, A, and Foa, R

Published
2017

9. Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Author

Volpetti S, Zaja F, and Fanin R

Subjects
hemic and lymphatic diseases, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract

Stefano Volpetti, Francesco Zaja, Renato FaninDivision of Hematology and Cellular Therapies Unit “Carlo Melzi”, Department of Experimental and Clinical Sciences, University Hospital “Santa Maria della Misericordia”, Udine, ItalyAbstract: Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is a promising aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity, and has been investigated in solid and hematologic tumors in several Phase I, II, and III trials. The aim of this review is to summarize the data reported so far on pixantrone as a salvage therapy in relapsed/refractory non-Hodgkin B-cell lymphoma.Keywords: pixantrone, aggressive non-Hodgkin B-cell lymphoma, relapsed/refractory

Published
2014

10. THROMBOPOIETIN RECEPTOR AGONIST SWITCHING IN ADULT IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM 8 ITALIAN CENTERS

Author

Carpenedo M, Cantoni S, Mazzucconi MG, De Stefano V, Ruggeri M, Vianelli N, Zaja F, Barcellini W, Nichelatti M, Coccini V, Baldacci E, Rossi E, Ciminello A, CAIROLI R, Carpenedo, M, Cantoni, S, Mazzucconi, M, De Stefano, V, Ruggeri, M, Vianelli, N, Zaja, F, Barcellini, W, Nichelatti, M, Coccini, V, Baldacci, E, Rossi, E, Ciminello, A, and Cairoli, R

Subjects
hematology
Published
2015

11. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

Author

Viviani S., Rambaldi A., Brusamolino E., Levis A., Bonfante V., Vitolo U., Pulsoni A., Liberati A. M., Specchia G., Valagussa P., Rossi A., Zaja F., Pogliani E. M., Pregno P., Gotti M., Gallamini A., Rota Scalabrini D., Bonadonna G., Gianni A. M., Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi, ZINZANI, PIER LUIGI, Viviani, S, Zinzani, P, Rambaldi, A, Brusamolino, E, Levis, A, Bonfante, V, Vitolo, U, Pulsoni, A, Liberati, A, Specchia, G, Valagussa, P, Rossi, A, Zaja, F, Pogliani, E, Pregno, P, Gotti, M, Gallamini, A, Rota Scalabrini, D, Bonadonna, G, Gianni, A, Viviani S., Zinzani P.L., Rambaldi A., Brusamolino E., Levis A., Bonfante V., Vitolo U., Pulsoni A., Liberati A.M., Specchia G., Valagussa P., Rossi A., Zaja F., Pogliani E.M., Pregno P., Gotti M., Gallamini A., Rota Scalabrini D., Bonadonna G., Gianni A.M., Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi, Zinzani, Pl, Liberati, Am, Zaja, Francesco, Pogliani, Em, Gianni, Am, Michelangelo, Foundation, Gruppo Italiano di Terapie Innovative nei, Linfomi, and Intergruppo Italiano, Linfomi

Subjects
BEACOPP, Male, drug megadose, medicine.medical_treatment, hematologic disease, Salvage therapy, Kaplan-Meier Estimate, cancer risk, chemotherapy, law.invention, sepsis, Randomized controlled trial, law, cancer control, MED/15 - MALATTIE DEL SANGUE, Antineoplastic Combined Chemotherapy Protocols, advanced cancer, event free survival, cell transplant, disease, fertility, hybrid, ifosfamide, mopp, regimen, standard, vinorelbine, Etoposide, Remission Induction, article, leukemia, Hematopoietic Stem Cell Transplantation, General Medicine, Middle Aged, acute granulocytic leukemia, Hodgkin Disease, Combined Modality Therapy, Dacarbazine, priority journal, Vincristine, Female, radiation dose, medicine.drug, Human, survival rate, Adult, medicine.medical_specialty, Adolescent, overall survival, disease classification, Vinblastine, cancer growth, Disease-Free Survival, cardiopulmonary insufficiency, Bleomycin, Young Adult, cancer combination chemotherapy, medicine, cancer radiotherapy, follow up, Humans, controlled study, Hodgkin's Lymphoma, Cyclophosphamide, Proportional Hazards Models, Neoplasm Staging, Salvage Therapy, treatment duration, Antineoplastic Combined Chemotherapy Protocol, business.industry, Proportional hazards model, cancer staging, adolescent, adult, clinical protocol, Hodgkin disease, human, liver failure, major clinical study, salvage therapy, treatment outcome, ABVD, medicine.disease, Hodgkin's lymphoma, Surgery, Doxorubicin, Procarbazine, Proportional Hazards Model, Prednisone, business, Progressive disease
Abstract

BACKGROUND: BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). METHODS: We randomly assigned 331 patients with previously untreated and unfavorable Hodgkin's lymphoma (stage IIB, III, or IV, or an international prognostic score of ≥3 on a scale of 0 to 7, with higher scores indicating increased risk), to receive either BEACOPP or ABVD, each followed by local radiotherapy when indicated. Patients with residual or progressive disease after the initial therapy were to be treated according to a state-of-the-art high-dose salvage program. The median follow-up period was 61 months. RESULTS: The 7-year rate of freedom from first progression was 85% among patients who had received initial treatment with BEACOPP and 73% among those who had received initial treatment with ABVD (P=0.004), and the 7-year rate of event-free survival was 78% and 71%, respectively (P=0.15). A total of 65 patients (20 in the BEACOPP group, and 45 in the ABVD group) went on to receive the intended high-dose salvage regimen. As of the cutoff date, 3 of the 20 patients in the BEACOPP group and 15 of the 45 in the ABVD group who had had progressive disease or relapse after the initial therapy were alive and free of disease. After completion of the overall planned treatment, including salvage therapy, the 7-year rate of freedom from a second progression was 88% in the BEACOPP group and 82% in the ABVD group (P=0.12), and the 7-year rate of overall survival was 89% and 84%, respectively (P=0.39). Severe adverse events occurred more frequently in the BEACOPP group than in the ABVD group. CONCLUSIONS: Treatment with BEACOPP, as compared with ABVD, resulted in better initial tumor control, but the long-term clinical outcome did not differ significantly between the two regimens. (Funded by Fondazione Michelangelo; ClinicalTrials.gov number, NCT01251107.).

Published
2011

12. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors

Author

Ruggeri, M, Tosetto, A, Palandri, F, Polverelli, N, Mazzucconi, Maria Gabriella, Santoro, Cristina, Gaidano, G, Lunghi, M, Zaja, F, De Stefano, V, Sartori, R, Fazi, P, Rodeghiero, F, Gruppo Italiano Malattie EMatologiche dell'Adulto Anemia, GIMEMA Study ITP0311, Thrombocytopenias Working P. a. r. t. y., Ruggeri, M., Tosetto, A., Palandri, F., Polverelli, N., Mazzucconi, M.G., Santoro, C., Gaidano, G., Lunghi, M., Zaja, F., De Stefano, V., Sartori, R., Fazi, P., Rodeghiero, F, Ruggeri, M, Tosetto, A, Palandri, F, Polverelli, N, Mazzucconi, Mg, Santoro, C, Gaidano, G, Lunghi, M, Zaja, Francesco, De Stefano, V, Sartori, R, Fazi, P, and Rodeghiero, F.

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Epidemiology, TMP mimetic peptide, epidemiology, immune thrombocytopenic purpura, splenectomy, thrombosis, medicine.medical_treatment, Population, Splenectomy, Immune thrombocytopenic purpura, Thrombosis, TMP mimetic peptide, Young Adult, Risk Factors, Retrospective Studie, Internal medicine, medicine, Humans, Cumulative incidence, education, Child, Thrombopoietin, thrombosis, Retrospective Studies, Aged, Aged, 80 and over, education.field_of_study, Purpura, Thrombocytopenic, Idiopathic, business.industry, Incidence (epidemiology), Risk Factor, Medicine (all), Hematology, Middle Aged, medicine.disease, Immune thrombocytopenia, Surgery, Venous thrombosis, Settore MED/15 - MALATTIE DEL SANGUE, Thrombosi, Female, business, Human
Abstract

BACKGROUND: An increased risk of thrombosis has been reported in primary immune thrombocytopenia (ITP) and with the use of thrombopoietin (TPO) receptor agonists, on the basis of population studies using administrative databases. OBJECTIVES: To evaluate if the incidence of venous and arterial thrombosis in patients with primary ITP is higher than a clinically significant cut-off set at of 3% and 6.4%. PATIENTS/METHODS: We undertook a retrospective multicenter investigation in a large cohort of patients requiring at least one treatment for ITP, enrolled from the major tertiary Italian centers treating ITP. A total of 986 patients were analyzed. RESULTS: During a 3888 patient-year follow-up, 43 first thrombotic events occurred: 28 arterial and 15 venous, resulting in a cumulative incidence of 3.2% for arterial (95% CI, 2.0-5.0) and 1.4% (95% CI, 0.8-2.5) for venous thrombosis at 5 years. The annualized rates for 100 patient-years were 1.14 (95% CI, 0.84-1.54), 0.39 (95% CI, 0.23-0.65) and 0.71 (95% CI, 0.49-1.04) for total, venous and arterial thrombosis. Splenectomy, performed in 136 patients (13.7%), increased thrombotic risk (HR = 3.5, 95% CI) compared with non-splenectomized patients. Age > 60 years, more than two risk factors for thrombosis at diagnosis and steroid use were independently associated with an increased risk of thrombosis. CONCLUSIONS: In this study, we demonstrate that the 5-year cumulative incidence of venous and arterial thrombosis in ITP is well below the predefined thresholds. Venous and arterial thromboembolism are not frequent complications in ITP, except in particular settings, such as in splenectomized and elderly patients. © 2014 International Society on Thrombosis and Haemostasis.

Published
2014

14. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Author

Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Ceccarelli, M., Boccomini, C., Genuardi, E., Chiappella, A., Baldini, L., Rossi, G., Pulsoni, A., Di Raimondo, F., Rigacci, L., Pinto, A., Galimberti, S., Bari, A., Rota-Scalabrini, D., Ferrari, A., Zaja, F., Gallamini, A., Specchia, G., Musto, P., Rossi, F. G., Gamba, E., Evangelista, A., Vitolo, U., Fondazione Italiana Linfomi: Chiara Lobetti-Bodoni, Barbara, Mantoan, Elisa, Genuardi, Mario, Boccadoro, Marco, Ladetto, Giovannino, Ciccone, Andrea, Evangelista, Manuela, Ceccarelli, Carola, Boccomini, Annalisa, Chiappella, Barbara, Botto, Lorella, Orsucci, Umberto, Vitolo, Maria, Goldaniga, Francesca Gaia Rossi, Luca, Baldini, Chiara, Bottelli, Alessandra, Tucci, Giuseppe, Rossi, Alessandro, Pulsoni, Federico De Angelis, Eleonora, Russo, Maurizio, Martelli, Robin, Foà, Francesco Di Raimondo, Annalisa, Chiarenza, Luigi, Rigacci, Benedetta, Puccini, Alberto, Bosi, Antonello, Pinto, Mario, Petrini, Sara, Galimberti, Alessia, Bari, Stefano, Sacchi, Massimo, Federico, Delia, Rota-Scalabrini, Massimo, Aglietta, Angela, Ferrari, Isabel Alvarez De Celis, Francesco, Merli, Francesco, Zaja, Renato, Fanin, Claudia, Castellino, Andrea, Gallamini, Guido, Parvis, Giuseppe, Saglio, Tommasina, Perrone, Giorgina, Specchia, Pellegrino, Musto, Enrica, Gamba, Paolo, Corradini, Enrico Maria Pogliani, Anna Marina Liberati, Giuseppe, Leone, Caterina, Patti, Giuseppe, Fioritoni, Chiara, Rusconi, Enrica, Morra, Anna, Tonso, Giuseppina, Cabras, Emanuele, Angelucci, Andrea, Rossi, Alessandro, Rambaldi, Sergio, Cortelazzo, Sergio, Morandi, Lanza, Francesco, Giovanni, Pizzolo, Sergio, Amadori, Pier Luigi Zinzani, Caterina, Stelitano, Francesco, Nobile, Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U, Fondazione Italiana Linfomi, [Zinzani PL], Ladetto, M, Lobetti Bodoni, C, Mantoan, B, Ceccarelli, M, Boccomini, C, Genuardi, E, Chiappella, A, Baldini, L, Rossi, G, Pulsoni, A, Di Raimondo, F, Rigacci, L, Pinto, A, Galimberti, S, Bari, A, Rota Scalabrini, D, Ferrari, A, Zaja, Francesco, Gallamini, A, Specchia, G, Musto, P, Rossi, Fg, Gamba, E, Evangelista, A, and Vitolo, U.

Subjects
Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Consolidation Chemotherapy, Disease-Free Survival, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm, Residual, Oncogene Proteins, Fusion, Prognosis, Rituximab, Pathology, Lymphoma, Follicular lymphoma, Gastroenterology, Biochemistry, hemic and lymphatic diseases, Monoclonal, minimal resdual disease, bone marrow, follicular lymphomas, Oncogene Proteins, Hematology, Hazard ratio, medicine.anatomical_structure, Residual, Immunology, Cell Biology, medicine.drug, Murine-Derived, medicine.medical_specialty, Antibodies, NO, follicular lymphoma, Chemoimmunotherapy, Internal medicine, medicine, Fusion, business.industry, Follicular, medicine.disease, Minimal residual disease, Neoplasm, Bone marrow, business
Abstract

We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH translocation was determined on bone marrow cells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). Of 234 enrolled patients, 227 (97%) were screened at diagnosis. A molecular marker (MM) was found in 51%. Patients with an MM were monitored at 8 subsequent times. Of the 675 expected follow-up samples, 83% were analyzed. Conversion to PCR negativity predicted better progression-free survival (PFS) at all post-treatment times (eg, end of therapy: 3-year PFS, 72% vs 39%; P < .007). MRD was predictive in both maintenance (83% vs 60%; P < .007) and observation (71% vs 50%; P < .001) groups. PCR positivity at the end of induction was an independent adverse predictor (hazard ratio, 3.1; 95% confidence interval, 1.36-7.07). MRD is a powerful independent outcome predictor in FL patients who receive rituximab-intensive programs, suggesting a need to investigate its value for decision-making. This trial was registered at www.clinicaltrial.gov as #NCT01144364.

Published
2013

15. THE IELSG-32 TRIAL: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION VS HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA

Author

Ferreri, Ajm, Cwynarski, K, Pulczynski, E, Ponzoni, M, Politi, Ls, Ambrosetti, A, Vitolo, U, Ilariucci, F, Balzarotti, M, Fabbri, A, Tucci, A, Pisani, F, Levis, A, Cabras, Mg, D'Arco, M, Zaccaria, A, Angrilli, F, Guarini, Anna, Imola, M, Martelli, Maurizio, Cervetti, J, Zaja, F, Pinto, A, Liberati, M, Morra, E, Cortellazzo, Sf, Bassan, R, Foppoli, M, Citterio, G, Sassone, M, Scarfo, L, Cavalli, F, Finke, J, Reni, M, Zucca, E, and Illerhaus, G.

Published
2015

17. A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL)

Author

Govi, S., Riccardo Dolcetti, Ponzoni, M., Pasini, E., Mappa, S., Doglioni, C., Bertoni, F., Zaja, F., Montalban, C., Stelitano, C., Cabrera, M. E., Cavalli, F., Zucca, E., Ferreri, A. J., Govi, S, Dolcetti, R, Ponzoni, Maurilio, Pasini, E, Mappa, S, Doglioni, C, Bertoni, F, Zaja, F, Montalban, C, Stelitano, C, Cabrera, Me, Cavalli, F, Zucca, E, and Ferreri, Aj

Published
2011

18. Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the IELSG#27 TRIAL)

Author

Govi S, Dolcetti R, Pasini E, Mappa S, Ventre MB, Doglioni C, Bertoni F, Zaja F, Montalban C, Stelitano C, Cabrera ME, Cavalli F, Zucca E, Ferreri AJM, PONZONI , MAURILIO, Govi, S, Dolcetti, R, Ponzoni, Maurilio, Pasini, E, Mappa, S, Ventre, Mb, Doglioni, C, Bertoni, F, Zaja, F, Montalban, C, Stelitano, C, Cabrera, Me, Cavalli, F, Zucca, E, and Ferreri, Ajm

Published
2011

19. A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27)

Author

Govi, S., Riccardo Dolcetti, Ponzoni, M., Pasini, E., Doglioni, C., Bertoni, F., Cabrera, M. E., Stelitano, C., Zaja, F., Montalban Sanz, C., Cavalli, F., Zucca, E., Ferreri, A., Govi, S, Dolcetti, R, Ponzoni, M, Pasini, E, Doglioni, C, Bertoni, F, Cabrera, Me, Stelitano, C, Zaja, F, Sanz, Cm, Cavalli, F, Zucca, E, and Ferreri, A

Published
2010

20. A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE

Author

Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi L, Caligaris Cappio F, Reni M, Ferreri A., PONZONI , MAURILIO, Licata, G, Foppoli, M, Corazzelli, G, Zucca, E, Stelitano, C, Zaja, F, Fava, S, Paolini, R, Franzin, A, Politi, L, Ponzoni, Maurilio, Caligaris Cappio, F, Reni, M, and Ferreri, A.

Published
2010

22. RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE (HD-MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (HD-ARAC) FOR PATIENTS WITH PRIMARY CNS LYMPHOMA (IELSG # 20 TRIAL): TOLERABILITY, ACTIVITY AND SURVIVAL ANALYSES

Author

Ferreri AJM, Reni M, Foppoli M, Martelli M, Siakantaris M, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Gelemur M, Aondio GM, Avvisati G, Balzarotti M, Brandes A, Costa MJ, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, Ferreri, Ajm, Reni, M, Foppoli, M, Martelli, M, Siakantaris, M, Frezzato, M, Cabras, Mg, Fabbri, A, Corazzelli, G, Ilariucci, F, Rossi, G, Soffietti, R, Stelitano, C, Vallisa, D, Zaja, F, Gelemur, M, Aondio, Gm, Avvisati, G, Balzarotti, M, Brandes, A, Costa, Mj, Gomez, H, Guarini, A, Pinotti, G, Rigacci, L, Uhlmann, C, Ponzoni, M, Zucca, E, Caligaris-Cappio, F, and Cavalli, F

Published
2009

23. A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia

Author

Rossi, D, di Bergamo, Lt, Chiarenza, A, Bulian, P, Visco, C, Mauro, Fr, Morabito, F, Cortelezzi, A, Zaja, F, Forconi, F, Laurenti, L, Del Giudice, I, De Paoli, L, Vincelli, I, Rigolin, Gian Matteo, Marasca, R, Perbellini, O, Moreno, C, Del Poeta, G, Massaia, M, Zinzani, Pl, Montillo, M, Cuneo, Antonio, Foa, R, Gattei, V, and Gaidano, G.

Subjects
CLL, FCR, molecular analysis, FCR, molecular analysis, CLL, NO
Published
2014

24. RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT) WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL): THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) #20 TRIAL

Author

Ferreri JM, Foppoli M, Martelli M, Pangalis G, Frezzato M, Cabras G, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio G, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Reni M, Zucca E, Cavalli F., PONZONI , MAURILIO, Ferreri, Jm, Foppoli, M, Martelli, M, Pangalis, G, Frezzato, M, Cabras, G, Fabbri, A, Corazzelli, G, Ilariucci, F, Rossi, G, Soffietti, R, Stelitano, C, Vallisa, D, Zaja, F, Zoppegno, L, Aondio, G, Avvisati, G, Balzarotti, M, Brandes, Aa, Fajardo, J, Gomez, H, Guarini, A, Pinotti, G, Rigacci, L, Uhlmann, C, Ponzoni, Maurilio, Reni, M, Zucca, E, and Cavalli, F.

Published
2008

25. Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (PTS) with primary CNS lymphoma (PCNSL)

Author

Ferreri AJ, Foppoli M, Martelli M, Pangalis G, Frezzato M, Cabras G, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio G, Annibali O, Balzarotti M, Brandes A, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Reni M, Zucca E, Cavalli F., PONZONI , MAURILIO, Ferreri, Aj, Foppoli, M, Martelli, M, Pangalis, G, Frezzato, M, Cabras, G, Fabbri, A, Corazzelli, G, Ilariucci, F, Rossi, G, Soffietti, R, Stelitano, C, Vallisa, D, Zaja, F, Zoppegno, L, Aondio, G, Annibali, O, Balzarotti, M, Brandes, A, Fajardo, J, Gomez, H, Guarini, A, Pinotti, G, Rigacci, L, Uhlmann, C, Ponzoni, Maurilio, Reni, M, Zucca, E, and Cavalli, F.

Published
2008

29. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma

Author

Marchi E, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, ALINARI, LAPO, TANI, MONICA, STEFONI, VITTORIO, PILERI, STEFANO, BACCARANI, MICHELE, ZINZANI, PIER LUIGI, Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, Pileri S, Baccarani M, and Zinzani PL

Published
2005

30. Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients

Author

Sperotto, A., Damiani, D., Zaja, F., Patriarca, F., Geromin, A., Cerno, M., Stocchi, R., Mario Tiribelli, Skert, C., Rinaldi, C., Fanin, R., Sperotto, A, Damiani, D, Zaja, F, Patriarca, F, Geromin, A, Cerno, M, Stocchi, R, Tiribelli, M, Skert, C, Rinaldi, C, Fanin, R., Damiani, Daniela, Zaja, Francesco, Patriarca, Francesca, Tiribelli, Mario, and Fanin, Renato

Subjects
Adult, Male, Transplantation Conditioning, Adolescent, Remission Induction, Cytarabine, Hematopoietic Stem Cell Transplantation, Middle Aged, Prognosis, Carmustine, Combined Modality Therapy, Hodgkin Disease, Transplantation, Autologous, Survival Rate, Young Adult, Treatment Outcome, Italy, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Lymph Nodes, Melphalan, Etoposide
Abstract

Autologous stem cell transplantation (ASCT) is largely employed in primary resistant or recurrent Hodgkin's Lymphoma (HL), while its role early in the course of the disease is still controversial. Our purpose was to analyse the results of 51 high-risk HL patients autografted at our Institution and the role of possible prognostic risk factors for the outcome. Twelve (23.5%) patients were in complete remission at transplant and were transplanted as having an high risk disease; 20 (39.5%) patients were in partial response and 19 (37.0%) were transplanted as primary induction failure. At a median time of 38 (6-111) months from ASCT, 36 (70.5%) patients are alive in complete remission, 8 (15.5%) patients are alive with disease and 7 (14.0%) died for progression. Thirty out of 32 (94.0%) patients transplanted with responsive disease (either complete or partial response) are alive without disease. Six out of 19 (32.0%) patients transplanted with resistant disease are alive in complete remission. The overall survival of the entire population is 77.0% at 60 (14-151) months from diagnosis. Disease free survival of the 22 patients that achieved a complete remission after ASCT (16 in partial response and 6 with resistant disease) is 100%. In our experience, more than 90% of patients transplanted with responsive but high risk disease, seem achieving and maintaining a durable complete remission, and more than 30.0% of patients submitted to ASCT with refractory disease can be potentially rescued by transplant.

Published
2002

32. A SINGLE-ARM MULTI-CENTER TRIAL OF BENDAMUSTINE GIVEN WITH OFATUMUMAB (BENDOFA) IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA. GIMEMA CLL0809 PROTOCOL

Author

Cortelezzi, A., Liberati, Am, Sciume, M., Cuneo, A., Reda, G., Gritti, G., Laurenti, L., Zaja, F., Marasca, R., Chiarenza, A., Orsucci, L., Storti, S., Murru, R., Cascavilla, N., Gobbi, M., Mauro, Francesca Romana, Gregorini, A., Morabito, F., Fabris, S., Maura, F., Piciocchi, A., Vignetti, M., Neri, A., Rossi, D., Gaidano, G., Marinelli, M., Guarini, Anna, and Foa, Roberto

Published
2012

33. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome

Author

Patriarca, F, Damiani, D, Fanin, R, Grimaz, S, Geromin, A, Cerno, M, Sperotto, A, Silvestri, F, Zaja, F, Baccarani, M., Patriarca, F, Damiani, D, Fanin, R, Grimaz, S, Geromin, A, Cerno, M, Sperotto, A, Silvestri, F, Zaja, F, Baccarani, M., Patriarca, Francesca, Damiani, Daniela, Fanin, Renato, Grimaz, S., Geromin, A., Cerno, M., Sperotto, A., Silvestri, F., and Zaja, Francesco

Subjects
Adult, Male, Neutropenia, Graft Survival, Plasma Cells, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Middle Aged, Hematopoietic Stem Cells, Combined Modality Therapy, Thrombocytopenia, Transplantation, Autologous, Disease-Free Survival, Survival Rate, Treatment Outcome, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Leukapheresis, Multiple Myeloma
Abstract

Background and Objectives. Positive selection of peripheral blood stem cells (PBSC) has been investigated in multiple myeloma (MM) with the aims of reducing plasma cell (PC) contamination of the leukaphereses and improving clinical outcome of autografted patients. Design and Methods. In our center 39 untreated patients with stage II and III MM, younger than 65 years, started high-dose therapy consisting of 4 VAD cycles, collection of PBSC mobilized by 7 g/m(2) cyclophosphamide + G-CSF, and myeloablative treatment with 12 mg/kg busulfan plus 120 mg/m(2) melphalan. The leukaphereses from 23/39 patients (59%) were processed for positive selection of CD34(+) cells using an avidin-biotin immunoaffinity device. Results. A reduction of PC contamination of as much as 2 log was found in the post-selection products by a flow-cytometric technique using the monoclonal antibody Co 138 alternatively coupled with CD38 and cytoplasmatic kappa or lambda light chains in separate samples. Hematologic reconstitution and clinical outcome of the 23 patients reinfused with selected CD34(+) cells (SEL group) were compared with those of the 16 patients reinfused with unselected cells (UNSEL group). No significant differences were observed between the 2 groups with regards to the median duration of neutropenia and thrombocytopenia, the hematologic support required, the incidence of febrile episodes and bacteremias. At a median follow-up of 18 months (range 5-34) after ASCT, there were 7/23 (32%) continuous complete remissions (CR) in the SEL group and 4/16 (25%) in the UNSEL group; there were 10/23 (44%) continuous partial remissions (PR) and 5/16 (31%) in the SEL and UNSEL groups, respectively. Two patients in the UNSEL group and one patient in the SEL group died of progressive disease. Interpretation and Conclusions. Our data show that positive selection allows rapid engraftment of hematopoiesis and low morbidity. Although no significant difference was detected between the two groups in the frequency of CR and PR 3 and 18 months after ASCT, a longer follow-up is needed to evaluate definitively the effect of CD34(+) selection on the clinical outcome after ASCT

Published
2000

34. Safety and Efficacy of Bendamustine With Or Without Rituximab In the Treatment of Heavily Pretreated Lymphoma Patients. A Multicenter Retrospective Study

Author

Rigacci, L., Iannitto, E., Puccini, B., Antognoli, G., D'Arco, A., Orciuolo, E., Cortelazzo, S., Gaidano, G., Freilone, R., Patti, C., Zaja, F., Gobbi, M., Musto, P., Zinzani, P. L., Storti, S., Isidori, A., Bongarzoni, V., Carpaneto, A., Renzo, N. D., Musso, M., Scalabrini, D. R., Santagostino, A., Stelitano, C., Cascavilla, N., Liberati, Anna Marina, Sancetta, R., and Bosi, A.

Published
2010

36. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Author

Ferreri, A.J. Reni, M. Foppoli, M. Martelli, M. Pangalis, G.A. Frezzato, M. Cabras, M.G. Fabbri, A. Corazzelli, G. Ilariucci, F. Rossi, G. Soffietti, R. Stelitano, C. Vallisa, D. Zaja, F. Zoppegno, L. Aondio, G.M. Avvisati, G. Balzarotti, M. Brandes, A.A. Fajardo, J. Gomez, H. Guarini, A. Pinotti, G. Rigacci, L. Uhlmann, C. Picozzi, P. Vezzulli, P. Ponzoni, M. Zucca, E. Caligaris-Cappio, F. Cavalli, F.

Abstract

Background: Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven. We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma. Methods: This open, randomised, phase 2 trial was undertaken in 24 centres in six countries. 79 patients with non-Hodgkin lymphoma exclusively localised into the CNS, cranial nerves, or eyes, aged 18-75 years, and with Eastern Cooperative Oncology Group performance status of 3 or lower and measurable disease were centrally randomly assigned by computer to receive four courses of either methotrexate 3·5 g/m2 on day 1 (n=40) or methotrexate 3·5 g/m2 on day 1 plus cytarabine 2 g/m2 twice a day on days 2-3 (n=39). Both regimens were administered every 3 weeks and were followed by whole-brain irradiation. The primary endpoint was complete remission rate after chemotherapy. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00210314. Findings: All randomly assigned participants were analysed. After chemotherapy, seven patients given methotrexate and 18 given methotrexate plus cytarabine achieved a complete remission, with a complete remission rate of 18% (95% CI 6-30) and 46% (31-61), respectively, (p=0·006). Nine patients receiving methotrexate and nine receiving methotrexate plus cytarabine achieved a partial response, with an overall response rate of 40% (25-55) and 69% (55-83), respectively, (p=0·009). Grade 3-4 haematological toxicity was more common in the methotrexate plus cytarabine group than in the methotrexate group (36 [92%] vs six [15%]). Four patients died of toxic effects (three vs one). Interpretation: In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone. Funding: Swiss Cancer League. © 2009 Elsevier Ltd. All rights reserved.

Published
2009

38. BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB (R)-FND /- R MAINTENANCE IS EFFECTIVE AND SAFE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA ELDERLY PATIENTS: AN INTERGRUPPO ITALIANO LINFOMI (IIL) RANDOMIZED TRIAL

Author

Vitolo, U., Ladetto, M., Boccomini, C., Gamba, E., Alvarez, I., Baldini, L., Chiappella, A., Corradini, P., DE RENZO, A., DI RAIMONDO, Francesco, Evangelista, A., Gallamini, A., Guarini, A., Mantoan, B., Martelli, M., Orsucci, L., Parvis, G., Petrini, M., Pinto, A., Pozzi, S., Pulsoni, A., Rigacci, L., Russo, E., Tarella, C., Tucci, A., Zaja, F., Gallo, E., and MAINTENANCE IS EFFECTIVE AND SAFE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA ELDERLY PATIENTS AN INTERGRUPPO ITALIANO LINFOMI IIL RANDOMIZED TRIAL, BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB R. FND R.

Published
2009

39. GALLOELDERLY PATIENTS WITH UNTREATED ADVANCED STAGE FOLLICULAR LYMPHOMA (FL) TREATED WITH BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB (R)FND+/-RITUXIMAB MAINTENANCE: PRELIMINARY ANALYSIS OF A PROSPECTIVE RANDOMIZED STUDY 333

Author

Vitolo, U., Ladetto, M., Boccomini, C., Gamba, E., Baldini, L., Ceccarelli, M., Chiappella, A., DE RENZO, A., DI RAIMONDO, Francesco, Gallamini, A., Mantoan, B., Martelli, M., Alvarez, I., Parvis, G., Petrini, M., Pinto, A., Pozzi, S., Pulsoni, A., Rigacci, L., Tucci, A., Zaja, F., and Gallo, E.

Published
2008

40. Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Author

Mauro, F. R., Cortelezzi, A., Molica, S., Laurenti, L., Liso, V., Rizzi, R., Carella, A. M., DI RAIMONDO, Francesco, Marasca, R., Fioritoni, G., Brugiatelli, M., Musolino, C., Lauria, F., Buccisano, F., Zaja, F., Callea, V., Morabito, F., Massaia, M., Gentile, G., DEL GIUDICE, I., DE PROPRIS, M. S., DELLA STARZA, I., Marinelli, M., Santangelo, S., Nanni, M., Vignetti, M., Graziosi, A., Specchia, G., Cuneo, A., Guarini, A., Blood, AND R. FOÀ ., and Vol, P.

Published
2008

41. BRIEF CHEMOIMMUNOTHERAPY WITH RITUXIMAB (R)-FND /- R MAINTENANCE AS FIRST LINE TREATMENT IN ADVANCED FOLLICULAR LYMPHOMA (FL) IN ELDERLY: PRELIMINARY ANALYSIS OF A PROSPECTIVE RANDOMIZED TRIAL

Author

Vitolo, U., Ladetto, M., Boccomini, C., Gamba, E., Alvarez, I., Baldini, L., Ceccarelli, M., ANNALISA CHIAPPELLA, Corradini, P., Renzo, A., Di Raimondo, F., Gallamini, A., Guarini, A., Mantoan, B., Marrelli, M., Naso, V., Parvis, G., Petrini, M., Pinto, P., Pozzi, S., Pulsoni, A., Rigacci, L., Tarella, C., Tucci, A., Zaja, F., and Gallo, E.

Published
2008

43. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome

Author

Skert, C., Patriarca, F., Sperotto, A., Cerno, M., Filì, C., Zaja, F., Stocchi, R., Geromin, A., Daniela DAMIANI, Fanin, R., Skert, C, Patriarca, Francesca, Sperotto, A, Cerno, M, Fili, C, Zaja, Francesco, Stocchi, R, Geromin, A, Damiani, Daniela, and Fanin, Renato

Abstract

Scleroderma may be one of the most severe forms of chronic graft-versus-host disease (GVHD). We retrospectively evaluated its incidence, predictor variables and outcome in 133 patients who survived at least 4 months after allogeneic hematopoietic stem cell transplantation. The 5-year cumulative incidence was 15.5% in patients with chronic GVHD. The generalized form had a progressive course despite immunosuppressive therapy. Eosinophilia, autoimmune markers, and previous skin involvement by chronic GVHD with disorders of pigmentation were significantly associated with an increased probability of developing scleroderma.

Published
2006

49. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

Author

Gallamini, A., Stelitano, C., Calvi, R., Bellei, M., Mattei, D., Vitolo, U., Morabito, F., Martelli, M., Brusamolino, E., Iannitto, E., Zaja, F., Cortellazzo, S., Rigacci, L., Devizzi, L., Todeschini, G., Santini, G., Brugiatelli, M., Federico, M., Intergruppo Italiano Linfomi, Liberati, Anna Marina, Gallamini, A, Stelitano, C, Calvi, R, Bellei, M, Mattei, D, Vitolo, U, Morabito, F, Martelli, M, Brusamolino, E, Iannitto, E, Zaja, Francesco, Cortelazzo, S, Rigacci, L, Devizzi, L, Todeschini, G, Santini, G, Brugiatelli, M, and Federico, M.

Subjects
Male, medicine.medical_specialty, Multivariate analysis, Time Factors, B-CELL, Immunology, Peripheral T-cell lymphoma not otherwise specified, Antineoplastic Agents, Lymphoma, T-Cell, Biochemistry, Gastroenterology, NHL, REAL CLASSIFICATION, Peripheral T-cell lymphoma, new prognostic model, PROPOSAL, Internal medicine, medicine, Humans, Lupus Erythematosus, Systemic, NON-HODGKINS-LYMPHOMA, Stage (cooking), Neoplasm Staging, Retrospective Studies, RISK, Univariate analysis, Performance status, business.industry, Patient Selection, Cell Biology, Hematology, CHEMOTHERAPY, Middle Aged, medicine.disease, Prognosis, Combined Modality Therapy, Survival Analysis, Surgery, Lymphoma, Relative risk, Female, business, Follow-Up Studies, Stem Cell Transplantation
Abstract

To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification. Factors associated with a worse overall survival (OS) in a univariate analysis were age older than 60 years ( P = .0002), equal to or more than 2 extranodal sites ( P = .0002), lactic dehydrogenase (LDH) value at normal levels or above ( P < .0001), performance status (PS) equal to or more than 2 ( P ≤ .0001), stage III or higher ( P = .0001), and bone marrow involvement ( P = .0001). Multivariate analysis showed that age (relative risk, 1.732; 95% CI, 1.300-2.309; P < .0001), PS (relative risk, 1.719; 95% CI, 1.269-2.327, P < .0001), LDH level (relative risk, 1.905; 95% CI, 1.415-2.564; P < .0001), and bone marrow involvement (relative risk, 1.454; 95% CI, 1.045-2.023; P = .026) were factors independently predictive for survival. Using these 4 variables we constructed a new prognostic model that singled out 4 groups at different risk: group 1, no adverse factors, with 5-year and 10-year OS of 62.3% and 54.9%, respectively; group 2, one factor, with a 5-year and 10-year OS of 52.9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively ( P ≤ .0001; log-rank, 66.79).

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results